Analyzing the Role of Hematopoietic Growth Factors in Pregnancy-Related Anemia: A Narrative Review

Pregnancy-related anemia is a common and significant health concern that can impact maternal and fetal outcomes. Hematopoietic growth factors, including erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), and thrombopoietin (TPO), are essential regulators of hematopoiesis, influencing red blood cell, white blood cell, and platelet production. This review explores the role of these growth factors in pregnancy-related anemia, examining how they regulate erythropoiesis and immune responses during pregnancy. The article also addresses the therapeutic potential of these factors in managing anemia in pregnant women, highlighting their possible use in cases where conventional treatments, such as iron supplementation, may be insufficient. Erythropoietin, primarily produced by the kidneys, is the main growth factor involved in stimulating red blood cell production. During pregnancy, increased EPO production supports the expanding blood volume and the oxygen demands of the fetus. However, iron deficiency and other nutritional deficiencies can limit the effectiveness of EPO in addressing anemia. Additionally, G-CSF, a growth factor involved in neutrophil production, may have a supporting role in enhancing immune function and reducing infection risks in pregnant women with anemia. Thrombopoietin, involved in platelet production, may also be significant in managing anemia with platelet dysfunction in conditions like preeclampsia.